- Press Releases
- Notices
Press Releases To List
-
- Jul.22.2024R & D
- Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
-
- Jul.19.2024R & D
- European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
-
- Jul.18.2024R & D
- Opdivo® Intravenous Infusion Approved in South Korea in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Patients with Unresectable or Metastatic Urothelial Carcinoma
-
- Jul.12.2024Management / Finance
- Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation
-
- Jun.25.2024R & D
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
Notices To List
-
- Jun.21.2024Corporate
- Voting Results (Extraordinary Report) of the 76th Ordinary General Shareholders’ Meeting
-
- Jun.20.2024Corporate
- Notice to Resolutions Passed at The 76th Ordinary General shareholders’ Meeting
-
- May.23.2024Corporate
- Notice to Convene the 76th Ordinary General Shareholders' Meeting
-
- May.09.2024Corporate
- Posted presentation material of Merger Agreement with Deciphera Pharmaceuticals
-
- Sep.26.2023Corporate
- Corporate Report 2023 has been released.
About
![](/sites/default/files/2020-12/top_aboutus01.jpg)
![](/sites/default/files/2020-12/top_aboutus01_sp.jpg)
![](/sites/default/files/2020-12/top_aboutus02.jpg)
![](/sites/default/files/2020-12/top_aboutus02_sp.jpg)
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.